Page 45 - Read Online

Moriguchi et al. Hepatoma Res 2019;5:43 I http://dx.doi.org/10.20517/2394-5079.2019.20 Page 13 of 14

93. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, et al. Nonobese population in a developing country has a high prevalence of
nonalcoholic fatty liver and significant liver disease. Hepatology 2010;51:1593-602.
94. Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, et al. Characterization of hepatocellular carcinoma (HCC) in non-
alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9.
95. Schutte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, et al. Characterization and prognosis of patients with hepatocellular
carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol 2014;14:117.
96. Leung C, Yeoh SW, Patrick D, Ket S, Marion K, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-
alcoholic fatty liver disease. World J Gastroenterol 2015;21:1189-96.
97. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J
Gastroenterol 2009;44 Suppl 19:89-95.
98. Agrawal S, Agarwal S, Arnason T, Saini S, Belghiti J. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol
Hepatol 2015;13:1221-30.
99. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, et al. A single-center surgical experience of 122 patients with single and
multiple hepatocellular adenomas. Gastroenterology 2009;137:1698-705.
100. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive
histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010;34:1630-6.
101. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
102. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
103. Uppot RN, Sahani DV, Hahn PF, Gervais D, Mueller PR. Impact of obesity on medical imaging and image-guided intervention. Am J
Radiol 2007;188:433-40.
104. Kurmann A, Wanner B, Martens F, Klasen J, Stickel F, et al. Hepatic steatosis is associated with surgical-site infection after hepatic
and colorectal surgery. Surgery 2014;156:109-16.
105. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI)
for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008;7:350-7.
106. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver
fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
107. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, et al.; APRICOT Clinical Investigators. Development of a simple noninvasive
index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25.
108. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, et al. Transient elastography: a new noninvasive method for assessment of
hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
109. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, et al. Hepatocellular carcinoma risk prediction model for the general population: the
predictive power of transaminases. J Natl Cancer Inst 2012;104:1599-611.
110. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European
Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic
fatty liver disease. J Hepatol 2016;64:1388-402.
111. World Cancer Research Fund International/American Institute for Cancer Research. Continuous update project report: diet, nutrition,
physical activity and liver cancer. 2015. Available from: https://www.wcrf.org/sites/default/files/Liver-cancer-report.pdf [last accessed
on 24 Dec 2019]
112. Yun YH, Lim MK, Won YJ, Park SM, Chang YJ, et al. Dietary preference, physical activity and cancer risk in men: national health
insurance corporation study. BMC Cancer 2008;8:366.
113. Zhu Z, Jiang W, Sells JL, Neil ES, McGinley JN, et al. Effect of nonmotorized wheel running on mammary carcinogenesis: circulating
biomarkers, cellular processes, and molecular mechanisms in rats. Cancer Epidemiol Biomarkers Prev 2008;17:1920-9.
114. Corrado RL, Torres DM, Harrison SA. Review of treatment options for nonalcoholic fatty liver disease. Med Clin North Am
2014;98:55-72.
115. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, et al. Liraglutide safety and efficacy in patients with non-alcoholic
steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-90.
116. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver
and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC
Cancer 2011;11:20.
117. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent
manner: population-based and in vitro studies. Gut 2013;62:606-15.
118. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic
review and meta-analysis. Am J Gastroenterol 2013;108:881-91.
119. Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-
analysis. Scand J Gastroenterol 2013;48:78-87.
120. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated
with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012;107:46-52.
121. Chen J, Han Y, Xu C, Xiao T, Wang B. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver
diseases: a meta-analysis of cohort studies. Eur J Cancer Prev 2015;24:89-99.